SHSE:605033 (China)
Â
Class A
Â¥
17
+0.040 (+0.24%)
Jul 29
Business Description
Shaanxi Meibang Pharmaceutical Group Co Ltd
ISIN : CNE100005071
Share Class Description:
SHSE:605033: Class ATotal Employee Number:
1,117Compare
Compare
Traded in other countries / regions
605033.China Index Membership
SSE Composite Index IPO Date
2021-09-16Description
Shaanxi Meibang Pharmaceutical Group Co Ltd is engaged in the research and development, production and sales of pesticide formulations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.69 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 2.53 | |||||
Interest Coverage | 122.71 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.07 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.3 | |||||
3-Year EBITDA Growth Rate | -20.2 | |||||
3-Year EPS without NRI Growth Rate | -33.1 | |||||
3-Year FCF Growth Rate | 38 | |||||
3-Year Book Growth Rate | 2.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.91 | |||||
9-Day RSI | 48.63 | |||||
14-Day RSI | 44.89 | |||||
3-1 Month Momentum % | -24.63 | |||||
6-1 Month Momentum % | -18.52 | |||||
12-1 Month Momentum % | -23.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.39 | |||||
Quick Ratio | 2.02 | |||||
Cash Ratio | 1.29 | |||||
Days Inventory | 111.92 | |||||
Days Sales Outstanding | 58.99 | |||||
Days Payable | 157.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.87 | |||||
Dividend Payout Ratio | 0.28 | |||||
3-Year Dividend Growth Rate | -7.6 | |||||
Forward Dividend Yield % | 0.87 | |||||
5-Year Yield-on-Cost % | 0.87 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -2.56 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 35.34 | |||||
Operating Margin % | 8.59 | |||||
Net Margin % | 5.67 | |||||
EBITDA Margin % | 6.51 | |||||
FCF Margin % | 1.77 | |||||
OCF Margin % | 19.87 | |||||
ROE % | 4.69 | |||||
ROA % | 2.85 | |||||
ROIC % | 6.21 | |||||
3-Year ROIIC % | -29.17 | |||||
ROC (Joel Greenblatt) % | 8.33 | |||||
ROCE % | 4.44 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.5 | |||||
PE Ratio without NRI | 32.08 | |||||
PS Ratio | 2.41 | |||||
PB Ratio | 1.93 | |||||
Price-to-Tangible-Book | 2.14 | |||||
Price-to-Free-Cash-Flow | 170 | |||||
Price-to-Operating-Cash-Flow | 12.29 | |||||
EV-to-EBIT | 29.7 | |||||
EV-to-EBITDA | 29.7 | |||||
EV-to-Revenue | 1.93 | |||||
EV-to-FCF | 109.19 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 2.8 | |||||
Price-to-Graham-Number | 1.75 | |||||
| Price-to-Net-Current-Asset-Value | 7.76 | |||||
Earnings Yield (Greenblatt) % | 3.37 | |||||
FCF Yield % | 0.74 | |||||
Forward Rate of Return (Yacktman) % | -36.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shaanxi Meibang Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 958.877 | ||
| EPS (TTM) (Â¥) | 0.4 | ||
| Beta | 0.8011 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.08 | ||
| Volatility % | 40.24 | ||
| 14-Day RSI | 44.89 | ||
| 14-Day ATR (Â¥) | 0.69617 | ||
| 20-Day SMA (Â¥) | 17.1485 | ||
| 12-1 Month Momentum % | -23.86 | ||
| 52-Week Range (Â¥) | 15.81 - 34.69 | ||
| Shares Outstanding (Mil) | 135.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shaanxi Meibang Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shaanxi Meibang Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.100000 Cash Dividend | 2026-06-17 | 18.81 (-0.53%) | ||
| CNY 0.050000 Cash Dividend | 2025-12-10 | 21.32 (+0.19%) | ||
| CNY 0.100000 Cash Dividend | 2025-06-11 | 21.00 (-2.19%) | ||
| CNY 0.045000 Cash Dividend | 2024-12-19 | 12.79 (-1.99%) |
Show
Entries
Shaanxi Meibang Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033)'s stock price today?
The current price of SHSE:605033 is ¥17.00. The 52 week high of SHSE:605033 is ¥34.69 and 52 week low is ¥15.81.
When is next earnings date of Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033)?
The next earnings date of Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033) is .
Does Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033) pay dividends? If so, how much?
The Dividend Yield %  of Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033) is 0.87% (As of Today), Highest Dividend Payout Ratio of Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033) was 1.22. The lowest was 0.2. And the median was 0.61. The  Forward Dividend Yield % of Shaanxi Meibang Pharmaceutical Group Co Ltd(SHSE:605033) is 0.87%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shaanxi Meibang Pharmaceutical Group Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers